BIA Separations introduces PrimaS multi-mode ligand bioprocessing technology to facilitate development of advanced therapeutics

16Jun2020

Novel platform initially focussed on high-resolution industrial scale processing of therapeutic mRNA

Ajdovščina, Slovenia, 16 June 2020: BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction of its novel PrimaS™ ligand technology. The proprietary multi-use platform faciliates high-resolution and high speed processing and addresses many underserved but critical separation problems in the context of fast emerging advanced therapy medicinal products (ATMPs). The first application of PrimaS technology being made available is for mRNA purification addressing a rapidly growing interest in mRNA-based therapies.

As part of BIA Separations‘ CIMmultus™ range, PrimaS is a key addition to the company‘s mRNA purification toolbox, including Oligo dT-18, C4-HLD and SDVB chemistries. The platform harnesses mRNA capturing and polishing strategies, including dsRNA impurity removal and mRNA sizing options. All technologies are easily scalable from lab to manufacturing, and are able to provide better product quality than traditional purification systems.

mRNA manufacturing involves several complex bioprocessing steps beginning with plasmid DNA production and its linearization, followed by in vitro transcription (IVT). Both operations include finely balanced enzymatic reactions, utilizing a number of key raw materials. For the standards required for clinical applications, ultra-pure mRNA is required, with critical contaminants eliminated, including dsRNA, template DNA and respective enzymes, in addition to potential impurities from raw materials such as chromatin-like structures and endotoxins.

Significant progress has been made by reseachers around the globe to sharpen concepts that exploit mRNA-based therapeutics, with as examples, many protein replacement, immuno-oncology and vaccine approaches, already progressing to early clinical stages. COVID-19 exemplifies the need for these advancements, acting as a catalyst to now further accelerate such developments.

Ingo Nagler, Business Development Officer at BIA Separations, commented:From the very beginning, BIA Separations positioned itself as a technology-enabling company, supporting scientists to solve the most difficult separation challenges faced in the development of genetic medicines. The new PrimaS technology significantly contributes to this objective, whilst ensuring patient safety remains at the forefront of our work.“

To learn more about BIA Separations’ novel PrimaS technology,
please follow this link: https://www.biaseparations.com/en/products/monolithic-columns/products-for-preparative-applications/214/primas

To get access to our mRNA portfolio page,
please follow this link: https://www.biaseparations.com/en/featured/messenger-rna


Media contact
Sarah Jeffery
Zyme Communications
E: sarah.jeffery@zymecommunications.com
T: +44 (0)7771 730 919

To opt-out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

At BIA Separations
Kaja Tudja
Sales and Marketing Manager
E: marketing@monoliths.com
T: +386 (0)59 699 505

About BIA Separations www.biaseparations.com

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules. The company has research and production facilities in Slovenia, with sales offices and distributors throughout the world. BIA Separations’ mission is to develop and produce CIM® monolithic columns of highest quality and provide superior research and method development services for purification and analytics of biomolecules. In addition, the company aims to provide unique in-process control tools to better understand and control the bioprocesses.